Synapse - Brian Serencsits

Results (12)

Mathematical modeling of exposure measurements following high-dose targeted therapy using 131I-apamistamab: Analysis from the large multicenter phase III SIERRA trial

Meeting Abstract

Pandit-Taskar, N.; Chen, L. Y.; Serencsits, B.; Prasad, K.; Senglaub, T.; Zgaljardic, M.; Spross, J.; Desai, A.; Brodin, P.
Journal of Nuclear Medicine (2024)

Fulltext@MSK | Save

Modeling-based assessment of exposure measurements after high-dose targeted (131)I-apamistamab: Results and analyses from the phase III SIERRA trial

Meeting Abstract

Pandit-Taskar, N.; Chen, L.; Serencsits, B.; Prasad, K.; Senglaub, T.; Zgaljardic, M.; Spross, J.; Desai, A.; Brodin, P.
European Journal of Nuclear Medicine and Molecular Imaging (2024)

Fulltext@MSK | Save

Theranostic intratumoral convection-enhanced delivery of (124)I-omburtamab in patients with diffuse intrinsic pontine glioma: Pharmacokinetics and lesion dosimetry

Journal Article

Pandit-Taskar, N.; Zanzonico, P. B.; Grkovski, M.; Donzelli, M.; Vietri, S. M.; Horan, C.; Serencsits, B.; Prasad, K.; Lyashchenko, S.; Kramer, K.; more...
Journal of Nuclear Medicine (2024)

Fulltext@MSK | Save

Feasibility of safe outpatient treatment in pediatric patients following intraventricular radioimmunotherapy with (131)I-omburtamab for leptomeningeal disease

Journal Article

Prasad, K.; Serencsits, B. E.; Chu, B. P.; Dauer, L. T.; Donzelli, M.; Basu, E.; Kramer, K.; Pandit-Taskar, N.
EJNMMI Research (2024)

Fulltext@MSK | Save

Administration and radiation safety of high-dose Iomab-B (I131-apamistamab) demonstrated in multiple clinical settings: Experience from the large multicenter phase 3 SIERRA trial for targeted conditioning of patients with relapsed/refractory AML

Meeting Abstract

Serencsits, B.; Prasad, K.; Chen, L.; Senglaub, T.; Zgaljardic, M.; Brodin, P.; McNamara, K.; Desai, A.; Pandit-Taskar, N.
Journal of Nuclear Medicine (2023)

Fulltext@MSK | Save

Feasibility of high- dose targeted radiation with I131apamistamab in patients with relapsed/refractory AML: Dosimetry and radiation safety experience from the phase 3 SIERRA trial

Meeting Abstract

Pandit-Taskar, N.; Prasad, K.; Chen, L.; Senglaub, T.; Zgaljardic, M.; Brodin, P.; Serencsits, B.
European Journal of Nuclear Medicine and Molecular Imaging (2023)

Fulltext@MSK | Save

Yttrium-90 activity quantification in PET/CT–guided biopsy specimens from colorectal hepatic metastases immediately after transarterial radioembolization using micro–CT and autoradiography

Journal Article

Naydenov, N.; Teplov, A.; Zirakchian, M. Z.; Ruan, S.; Chu, B. P.; Serencsits, B.; Iraca, M.; Talarico, O.; Miller, B.; Kunin, H.; more...
Journal of Vascular and Interventional Radiology (2023)

Fulltext@MSK | Save

Impact of shield location on staff and caregiver dose rates for I-131 radiopharmaceutical therapy patients

Journal Article

Bellamy, M.; Chu, B.; Serencsits, B.; Quinn, B.; Prasad, K.; Altamirano, J.; Williamson, M.; Miodownik, D.; Abrahams, N.; Chen, F.; more...
Journal of Radiological Protection (2023)

Fulltext@MSK | Save

Cohort profile - MSK radiation workers: A feasibility study to establish a deceased worker sub-cohort as part of a multicenter medical radiation worker component in the million person study of Low-Dose radiation health effects